Surgical Robotics: Twenty Years of Near-Monopoly Comes to an End
The global surgical robots market is entering the most competitively consequential year in its history. For more than two decades since Intuitive Surgical introduced the da Vinci Surgical System in the early 2000s, the company has held an almost uncontested position in soft-tissue robotic surgery — a watershed moment that, as industry historians have observed, revolutionised minimally invasive surgery by giving surgeons enhanced dexterity, precision, and visualisation unavailable through conventional laparoscopy. Intuitive has placed more than 10,670 da Vinci systems in hospitals worldwide and, as of the fourth quarter of 2025 alone, shipped 532 systems, including 303 units of its latest da Vinci 5 platform, reflecting continued strong demand for its most advanced generation of technology. Yet 2026 marks the year this dominance is being genuinely tested, with MedTech Dive’s January 2026 analysis of robotic surgery trends identifying the emergence of credible, well-capitalised, FDA-cleared competitors as the defining theme of the year ahead.
The Competitive Floodgates Open: Medtronic, CMR Surgical, and J&J
December 2025 marked a genuine inflection point for the competitive landscape. MedTech Dive reported that Medtronic’s Hugo robotic surgery system received FDA clearance for urologic procedures in December 2025, with the company also pursuing indications in general surgery and gynaecology. In the same month, CMR Surgical secured FDA clearance for its Versius Plus system. Jefferies analyst Matthew Taylor characterised the moment plainly: Medtronic now has U.S. approval and will move ahead with a limited launch, with potential growth impact for the company emerging as early as the following year, while Johnson & Johnson — in the process of obtaining its own approval for the Ottava system — is unlikely to have a material competitive impact until 2028 at the earliest. Industry adviser Steve Bell, who consults with medtech startups, told MedTech Dive that Medtronic and J&J represent the first tier of large multinationals positioned to challenge Intuitive head-on in the soft-tissue robotics race, while a second tier of smaller, specialised companies will instead pursue differentiation in sites of care that Intuitive has not yet penetrated.
J&J MedTech’s Ottava programme continued its regulatory advance into January 2026, when the company officially submitted the system to the FDA for De Novo classification, targeting upper abdominal general surgery applications and incorporating machine-learning-based collision prediction — a capability designed to enhance intraoperative safety during complex multi-arm procedures. CMR Surgical’s Versius Plus, cleared in February 2026, was engineered with rapid modularity as its central design philosophy: the system’s arms detach in under ten minutes, directly addressing hospital demand for robots that can be moved efficiently between operating rooms without lengthy recalibration — a meaningful departure from the fixed-cart architecture that has defined much of the installed base to date.
Intuitive Surgical’s Response: Innovation, Confidence, and a More Conservative Forecast
Facing its first genuine soft-tissue competition in over twenty years, Intuitive has responded with continued platform innovation rather than retreat. In January 2026, the company received FDA clearance for cardiac surgery applications on its da Vinci 5 platform, including mitral valve repair and coronary artery bypass grafting — expanding its addressable procedure base into one of surgery’s most demanding and highest-value specialties. The company has also added new features including video replay capability to support real-time surgical decision-making and a force-sensing gauge that measures the pressure surgeons apply to tissue during procedures.
Notably, MedTech Dive’s reporting on Intuitive’s 2026 guidance revealed that the company provided a worldwide da Vinci procedure growth forecast of approximately 13% to 15% for 2026, below the roughly 18% growth rate achieved the prior year — a deceleration the company’s executives attributed not to direct competitive pressure but to potential impacts from changes to Affordable Care Act premium subsidies and Medicaid funding in the United States, capital expenditure challenges among hospital customers in Europe and Japan, and intensifying competition specifically within the Chinese market. Intuitive CEO Dave Rosa told investors at the J.P. Morgan Healthcare Conference that he liked the company’s chances against the new entrants, and Jefferies’ Taylor noted that Intuitive typically issues conservative initial-year guidance and has historically outperformed it — a pattern he expects to continue, supported by sustained adoption of the da Vinci 5 platform.
Sites of Care: The Decisive 2026 Battleground
Perhaps the most strategically important insight from the current competitive cycle is where the contest will actually be fought. Bell’s prediction to MedTech Dive was direct: the most significant area of competitive differentiation in 2026 will be new sites of care, with smaller and emerging companies specifically targeting hospitals that have not yet established any robotics programme at all — rather than attempting to displace entrenched da Vinci installations in hospitals that have already invested heavily in Intuitive’s ecosystem of training, instruments, and service contracts. Bell anticipates that initial interest in Medtronic’s Hugo system will come disproportionately from surgeons and institutions already loyal to Medtronic’s broader surgical instrument portfolio, from academic institutions seeking platform diversity for research and training purposes, and from surgeons who have simply never adopted an Intuitive robot. He described the near-term impact as meaningful only within a relatively small percentage of the overall market — but meaningful nonetheless, with the cumulative effect of Medtronic in 2026 and J&J in subsequent years expected to compound.
This dynamic is also reshaping the competitive map geographically. Companies less well known within the U.S. market — including Shanghai-based MicroPort MedBot and Medicaroid, a Japanese joint venture between Kawasaki Heavy Industries and Sysmex — are simultaneously increasing their global reach, reflecting the genuinely international character of the current competitive cycle. China’s strategic policy initiatives, including provisions within its national Five-Year Plans, have channelled substantial state-directed investment into domestic medical robotics development, with Chinese manufacturers increasingly developing cost-competitive systems aimed first at the enormous domestic market and increasingly at international expansion.
AI Integration and the Path Toward Autonomous Surgical Assistance
Artificial intelligence is rapidly becoming the primary axis of product differentiation across the surgical robotics industry, layered on top of the underlying hardware competition. J&J MedTech announced in October 2025 that it is incorporating AI-driven simulation into its MONARCH Platform for Urology, creating virtual operating room environments that assist clinical teams in configuring the robotic system before a procedure begins — with the platform expected to become commercially available in the United States during 2026. Medtronic’s Stealth AXiS spine robot, which received FDA clearance in February 2026, integrates advanced imaging directly with surgical navigation to guide pedicle-screw placement within sub-millimetre tolerances, addressing one of spine surgery’s most safety-critical technical challenges.
The orthopaedic segment is moving even more decisively toward autonomy. Zimmer Biomet’s acquisition of Monogram Technologies for approximately $177 million in October 2025 brought the company CT-based, semi-autonomous, AI-navigated total knee arthroplasty technology — combining machine vision, CT-based navigation, and autonomous surgical execution capability — explicitly advancing Zimmer Biomet’s ambitions toward fully autonomous orthopaedic robotic systems. Regulators are racing to keep pace with this acceleration: the FDA’s 2026 guidance agenda includes finalising lifecycle management rules specifically for AI-enabled medical devices, building on the agency’s January 2025 draft guidance establishing a Total Product Life Cycle framework for AI-enabled device software functions. In a notable instance of international regulatory coordination, the FDA and the European Medicines Agency jointly published ten guiding principles for good AI practice in medicines and device development in January 2026 — though substantial divergence between national regulatory regimes continues to complicate multinational product rollouts for surgical robotics manufacturers.
New Entrants and the Democratisation of Surgical Robotics Cost Structures
A parallel and equally significant trend is the emergence of lower-cost, modular surgical robotics aimed at expanding access beyond the large academic medical centres that have historically dominated robotic surgery adoption. Microbot Medical’s Liberty Endovascular Robotic System represents one of the most distinctive examples of this trend: the device is small enough to fit in the palm of a hand, is entirely single-use, and arrives completely sterile off the shelf — eliminating the re-sterilisation processes, drape waste, and behavioural change historically required to integrate robotic systems into existing clinical workflows. Company representatives have described the system as allowing physicians to begin a procedure within minutes of opening the device, with no equipment to clean or re-sterilise once the case is complete.
This democratisation trend extends across multiple companies pursuing fundamentally different cost and form-factor strategies than the traditional multi-arm cart-based systems that have defined the industry since Intuitive’s founding. Emerging companies including Vicarious Surgical and Moon Surgical have focused on modular add-on devices priced around $50,000 that retrofit onto existing laparoscopic equipment towers already present in operating rooms — a strategy explicitly designed to appeal to budget-constrained hospitals and ambulatory surgical centres that cannot justify the multi-million-dollar capital outlay and the minimum annual procedure volume required to break even on a traditional multi-port robotic system. Venture capital has responded accordingly: among the largest medtech venture rounds raised since 2023, several of the most significant were directed specifically at operating-room robotics companies, including funding rounds for Distalmotion, CMR Surgical, and Medical Microinstruments, reflecting strong continued investor conviction in the sector’s growth trajectory even amid Intuitive’s historical dominance.
Reimbursement, Ambulatory Surgical Centres, and the Expanding Site of Care
Reimbursement policy continues to play a decisive role in shaping where and how quickly robotic surgery adoption expands. The U.S. Centers for Medicare & Medicaid Services finalised and released a payment rate for lymphovenous bypass procedures performed in the outpatient setting within the CY 2026 Outpatient Prospective Payment System Final Rule, creating initial formal reimbursement for a procedure that, until this rule, required billing under unlisted surgical codes — with the resulting new Category III code, effective January 1, 2026, intended to capture both manual and robotic-assisted versions of the procedure and to enable the systematic data collection needed to support further reimbursement pathway development. More broadly, CMS’s ongoing expansion of robotic procedures eligible for the Ambulatory Surgical Center Covered Procedures List, combined with the proliferation of compact, cart-based robotic systems specifically suited to smaller surgical suites, is enabling ambulatory centres to capture a growing share of robotic procedure volume — and to do so at materially higher margins than traditional inpatient hospital settings, given the lower overhead structure of ambulatory care.
Competitive Landscape & Key Players: A Market Bifurcating Into Tiers
The global surgical robotics competitive landscape is bifurcating into increasingly distinct tiers. At the top, Intuitive Surgical continues to control the overwhelming majority of global soft-tissue robotic procedure volume, supported by a portfolio that now exceeds 4,200 active patents, the majority concentrated in computer vision and predictive analytics — an intellectual property moat that newer entrants will need years to approach. Stryker’s Mako platform remains the clear leader in orthopaedic joint replacement robotics, with its SmartRobotics technology and sensor-augmented arms collecting force data at rates exceeding 1,000 hertz during bone-cutting procedures, generating a substantial proprietary dataset for training future predictive surgical algorithms. Medtronic, fresh off its Hugo clearance, established a dedicated robotic surgery research and training centre in Korea in December 2024, reflecting the company’s long-horizon investment in surgeon education infrastructure as a competitive differentiator alongside the hardware itself.
Among the second tier of challengers, CMR Surgical’s modular Versius platform and Zimmer Biomet’s newly acquired autonomous knee technology represent two of the most credible near-term competitive threats in their respective specialties, while companies including Microbot Medical, Vicarious Surgical, and Moon Surgical are pursuing genuinely disruptive cost and form-factor innovation rather than competing directly on Intuitive’s own terms. Constancy Researchers identifies the central strategic question for the remainder of the decade as whether incumbents can defend their installed-base advantages — built on surgeon training, instrument ecosystems, and service relationships — against challengers offering meaningfully lower capital costs, greater modularity, and increasingly sophisticated AI-native capabilities built without the constraints of legacy hardware architecture.
What Does the 2026 Surgical Robotics Inflection Point Mean for the Decade Ahead?
Constancy Researchers’ assessment is that 2026 will be remembered as the year the surgical robotics industry definitively transitioned from a single-company story to a genuinely competitive market. Intuitive Surgical’s clinical and commercial advantages — its enormous installed base, its surgeon training infrastructure, and its multi-thousand-patent intellectual property position — remain formidable, and the company’s own leadership has expressed confidence that these advantages will continue to support strong growth even as the competitive environment intensifies. But the simultaneous arrival of FDA-cleared competition from Medtronic and CMR Surgical, the advancing regulatory progress of J&J’s Ottava system, the rapid embedding of AI-driven autonomy across orthopaedic and soft-tissue applications alike, and a wave of disruptive low-cost modular entrants together represent the most significant structural change in the industry’s competitive architecture since Intuitive itself entered the market over two decades ago. The hospitals, surgeons, and investors that navigate this transition most successfully will be those that recognise the contest is increasingly being fought not over existing da Vinci installations, but over the much larger population of sites of care that have not yet adopted robotic surgery at all — and over which company’s AI-enabled software, rather than hardware alone, ultimately proves most capable of improving surgical outcomes.
Looking to navigate geopolitical risks and identify new industry opportunities?
Connect with Constancy Researchers for data-driven insights, geopolitical intelligence, and strategic consulting tailored to your business needs.
